(Q37103929)

18 August 2017

Influenza and respiratory syncytial virus in the elderly (English)

1 reference

18 August 2017

Alex J Elliot

1

1 reference

PubMed ID

18324893

18 August 2017

Douglas M Fleming

series ordinal

2

1 reference

18 August 2017

1 March 2008

1 reference

Expert Review of Vaccines

18 August 2017

1 reference

18 August 2017

7

1 reference

18 August 2017

249-258

1 reference

18 August 2017

2

1 reference

The global impact of influenza on morbidity and mortality

18 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Mapping the antigenic and genetic evolution of influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Characterization of the 1918 influenza virus polymerase genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Avian influenza A (H5N1) in 10 patients in Vietnam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

H5N1 influenza--continuing evolution and spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Are we ready for pandemic influenza?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Human infection with influenza H9N2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Safety and prophylactic efficacy of low-dose rimantadine in adults during an influenza A epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

The role of antivirals in the control of influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Emergence and apparent transmission of rimantadine-resistant influenza A virus in families

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Low incidence of rimantadine resistance in field isolates of influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

High prevalence of amantadine-resistance influenza a (H3N2) in six prefectures, Japan, in the 2005-2006 season.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Distribution of amantadine-resistant H5N1 avian influenza variants in Asia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Early administration of oral oseltamivir increases the benefits of influenza treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Human disease from influenza A (H5N1), Thailand, 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Oral oseltamivir treatment of influenza in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Oseltamivir resistance during treatment of influenza A (H5N1) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Avian flu: isolation of drug-resistant H5N1 virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Influenza vaccine uptake and distribution in England and Wales using data from the General Practice Research Database, 1989/90-2003/04.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

The unmet need in the elderly: designing new influenza vaccines for older adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Influenza vaccination: policy versus evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Mortality benefits of influenza vaccination in elderly people: an ongoing controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Risk factors for severe respiratory syncytial virus infection in elderly persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

The impact of influenza epidemics on hospitalizations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Influenza-associated hospitalizations in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

The association of respiratory syncytial virus infection and influenza with emergency admissions for respiratory disease in London: an analysis of routine surveillance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Respiratory syncytial virus infection in elderly and high-risk adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Respiratory syncytial virus and influenza A infections in the hospitalized elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Influenza- and RSV-associated hospitalizations among adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Epidemiology of pandemic influenza: use of surveillance and modeling for pandemic preparedness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Mortality associated with influenza and respiratory syncytial virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Influenza and its relationship to circulatory disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Effectiveness of influenza vaccine in the community-dwelling elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Impact of influenza vaccination on major cause-specific mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Additive preventive effect of influenza and pneumococcal vaccines in elderly persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Influenza Vaccination Among the Elderly in the United States—Reply

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Immunopathogenesis of vaccine-enhanced RSV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

A case–control study of elderly patients with acute respiratory illness: Effect of influenza vaccination on admission to hospital in winter 2003–2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.249

21 January 2018

Identifiers

DOI

10.1586/14760584.7.2.249

1 reference

18 August 2017

1 reference

PubMed ID

18324893